Polymorphisms in Pharmacogenetics of Personalized Cancer Therapy by Kocal, Gizem Calibasi & Baskin, Yasemin
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
Polymorphisms in Pharmacogenetics of Personalized
Cancer Therapy
Gizem Calibasi Kocal and Yasemin Baskin
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69207
Abstract
Therapy process of personalized cancer management covers surgery, chemotherapy, 
radiation therapy and targeted therapies. The choice of cancer chemotherapeutic agents 
and doses depends upon the location and stage of tumor, as well as the general state of 
the patient. On the chemotherapy, radiotherapy, and targeted therapy processes, phar-
macogenetics offers customized solutions according to the personal genetic information. 
Especially for clinicians, genetic information obtained from polymorphism-based phar-
macogenetic tests is highly crucial for the better prediction ability of drug response and 
life-threatening toxic reactions due to the narrow therapeutic index of cancer chemo-
therapeutic agents. Pharmacogenotyping utilizes different examination strategies, such 
as single nucleotide polymorphism analysis, somatic/germline mutation analysis and 
partial/full genome sequencing. The promising effect of pharmacogenetics on the solving 
of the individual variability in drug response and toxic reactions is being observed with 
the accumulation of the information that unravel the human genomic variations from 
large-scale population and multi-parameter-based pharmacogenetic studies of the post-
genomic era. Polymorphisms contribute wide variations in human genome and may 
define how individuals respond to medications, either by changing the pharmacokinet-
ics and pharmacodynamics of drugs or by altering the cellular response to therapeutic 
agents. To define the effect of polymorphisms on the targets of chemotherapeutics is 
necessary for the prediction of altered pharmacokinetics of therapeutic agents.
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1. Introduction
1.1. Genetic polymorphisms
1.1.1. Mutation or polymorphism
Genetic and environmental factors are the two main reasons that cause human phenotype 
variations. If the genomic DNA sequences of two individuals are compared, substantial 
sequence variations can be detected at different points of the whole genome. There are many 
forms of these genetic variations [1]. Polymorphism term, arose from the combination of the 
Greek words ‘poly’ (meaning as multiple) and ‘morph’ (meaning as form), is used in genet-
ics to describe multiple forms of a single gene that exist in a population. Polymorphisms are 
genetic variants and refer to the occurrence of various phenotypes in a certain population. 
A polymorphism is a DNA sequence variation and does not classify as mutation. In genetic 
polymorphisms, there are two or more equally acceptable sequence of a gene and the com-
mon allele must have a frequency of 1% or more in the population. If the frequency is lower 
than 1%, the allele is accepted as a mutation. On the other hand, a mutation is a change in 
DNA sequence away from normal allele and forms abnormal variant [2].
1.1.2. Nomenclature
The unique and universal nomenclature to refer specific single nucleotide polymorphisms 
(SNPs) is that using the rs number (reference sequence). It stands for Reference SNP clus-
ter ID. The rs number allows the precise identification of a polymorphic variation in the 
numerous databases (NCBI, HapMap, SNP500 Cancer, etc.). For instance, a SNP causes a 
replacement of an amino acid by another amino acid; this can be defined by the name and 
the position of the replaced amino acid, followed by the name of the novel amino acid. 
As an example, a  common SNP in the DPYD gene is identified as rs 1801160 [V732I or 
Val732Ile]. SNPs are also identified by the name and position of nucleotide in the reference 
DNA sequence. The same SNP in the DPYD gene, presented with rs 1801160, is identified as 
2194G>A. The letters A, T, C, and G can be used for both nucleotides and amino acids, and 
this can cause confusion [3].
1.1.3. Types of polymorphisms
Developments in next generation sequencing technologies under the “Human Genome 
Project,” simplify to investigate the allelic variants of a gene taken from different people 
of a population [4]. These various genetic polymorphisms include minor changes on DNA 
sequence, as substitutions, deletions, insertions, and repeats. These changes influence the 
three-dimensional structure, expression and activity of the proteins encoded by these genes. 
Alterations called as single nucleotide polymorphisms (SNPs, pronounced snip) are the most 
common form of polymorphisms on a gene sequence. They occur when alleles reveal only a 
single base pair (bp) change—A, T, C or G—in the genome sequence between individuals. 
For example, one variant may have an A nucleotide at a certain position and other has a G 
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nucleotide (Figure 1). This type of change generates single nucleotide variants (SNVs). SNPs 
can affect gene function due to the change of protein but can also occur in noncoding parts of 
the gene so they would not be seen in the protein product [5, 6].
1.1.4. Polymorphisms and ethnicity
Intrinsic factors and extrinsic factors cause variability in drug response. Extrinsic factors such as 
food and concomitant medications may be controllable, but intrinsic factors such as gender, eth-
nicity, age, renal or hepatic function, and genetic differences in the expression of enzymes need 
advance knowledge to control [7]. Ethnicity is one of the key factors that can explain the observed 
variability in both pharmacokinetics (PK) and pharmacodynamics (PD) of therapeutics, result-
ing in differences in response to drug therapy as well as chemotherapeutics. United States Food 
and Drug Administration (FDA) guidelines pay attention to “ethnically sensitive situations” 
for some drugs and suggests the types of solutions that may control such ethnic sensitivity. 
One of the most important factors that may contribute to this ethnic sensitivity of a drug, include 
genetic polymorphisms in metabolic pathways of drugs [7, 8]. To define the variability on the 
response or metabolism of specific therapeutics or drug targets, drug companies and presti-
gious research groups are biobanking DNA samples [9]. Although the clinical relevance of some 
variants is well characterized, the relevance of some variant alleles is as yet unknown.
1.1.5. Allele frequency and Hardy-Weinberg principle
There are some challenges on the use of disease-associated polymorphism knowledge. One 
of these challenges is the lack of the unique information regarding the frequency of spe-
cific polymorphism in the targeted population. Without a unique presenting style of the 
Figure 1. Classes of DNA variation affecting a single nucleotide position. (A) Single nucleotide variant (SNV) in which 
two variants differ by having a G nucleotide or a C nucleotide (B) Insertion variation in which variant 1 has exactly 
same reference sequence, variant 2 has one more T nucleotide; Deletion variation in which variant 1 has a A nucleotide, 
variant 2 does not have; (C) Variable number of tandem repeats (VNTR) in which two variants differ by having repeats 
of nucleotides.
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 polymorphism-related data, prevention of the risk for disease and drugs remain unknown. 
In addition, determining the factors that may affect the association of the allele with disease 
or drugs, such as ethnicity, may not be possible without population-based allele frequencies 
[10–12]. SNPs can be assigned with an allele frequency—the ratio of chromosomes in the pop-
ulation carrying the less common variant to those with the more common variant. It is impor-
tant to note that there are variations among different populations, so a common SNP allele may 
be much rare in one geographical or ethnic group than another [13, 14]. The Hardy-Weinberg 
principle can be used to calculate allele frequencies [15]. The Hardy-Weinberg principle (also 
known as the Hardy-Weinberg equilibrium, equation, theorem, or law) states that allele fre-
quencies in a population will remain stable from generation to generation in the absence of 
other evolutionary factors, such as mutation, polymorphisms, genetic drift, gene flow, meiotic 
drive, and mate choice. Hardy-Weinberg principle describes that the ideal condition against 
the effects of these factors can be analyzed. The principle is named after Godfrey Harold 
Hardy and Wilhem Weinberg, who first demonstrated it mathematically. If Hardy-Weinberg 
principle is violated, the key interferences of a genetic polymorphisms-based study may be 
compromised. Thus, accumulating evidence suggests that Hardy-Weinberg principle-based 
reporting may be optimal in genetic and nongenetic journals, because variability in the ana-
lyzed data can cause errors or peculiarities [15].
2. Polymorphisms-based pharmacogenetics applications and 
personalized cancer therapy
Most of the chemotherapeutic agents for cancer treatment affect a minority of cancer patients 
and have a narrow therapeutic index that frequently causes life-threatening toxicities and 
even death. Even specific molecule-targeted therapies, which are safer than cytotoxic drugs, 
are associated with severe adverse events. Thus, novel treatment strategies that can increase 
the effectiveness of therapy and decrease the rate of adverse events will be developed. Under 
this approach, the aim of personalized medicine is to tailor the therapy options according to 
patient’s molecular profile [16, 17]. Establishing the relation between molecular characteris-
tics of patient and drug outcomes is crucial for the identification of predictive biomarkers and 
understands the base of personalized therapy. Personalized medicine can also be called as P4 
medicine due to the various contents as predictive, personalized, preventive, and participa-
tory medicine (P4); it separates patients into different groups with an individual’s molecular 
profile. Thus, personalized medicine covers the determination of the safest and most effec-
tive chemotherapeutic agents [18]. The goal of discipline of pharmacogenetics, first used in 
the late 1950s, is to make ‘personalized medicine’ as applicable to various patient groups. 
It can be defined as the study of patients’ genotype affecting drug response. In some patient 
groups, certain drugs work well but not as well in others. Pharmacogenetics-based studies 
(between genotype of patients and the response of therapeutics) allow designing more effec-
tive and population-specific therapeutic treatments (Figure 2). Polymorphism analysis, muta-
tion analysis and genome sequencing are the backbones of discipline of pharmacogenetics. 
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Polymorphisms and their association with  diseases should be handled based on gene as bio-
markers, due to the relatively large frequency in the human genome. To learn, how to use and 
interpret the polymorphisms analysis and which test(s) should be chosen is essential.
2.1. Methods for polymorphism detection
After the deep sequencing of human genome with Human Genome Project, the detection 
of population-based DNA polymorphisms, especially that effect the development and the 
progress of diseases, is the second phase of human genomics. High-throughput polymor-
phism genotyping process includes fast and cost-effective identification of polymorphisms 
in different individuals and lead to the determination of associations between genotype and 
phenotype. Generally, genotyping steps start with the isolation of starting material as DNA 
from patient; it follows with amplification to increase the sample amount and then finalize 
with polymerase chain reaction (PCR), sequencing or array-based technologies. A number of 
good polymorphism genotyping technologies are currently in use to meet the needs of clinics 
and researches, but only one genotyping method is not ideal for all applications (Table 1). 
Slow speed of assays due to the time-consuming protocols, high instrument and consumable 
costs, and requirements on the performing multiple assays in parallel are the main challenges 
of polymorphism genotyping technologies. Studies on ideal polymorphism genotyping tech-
nologies are on development process [19–21].
Figure 2. The traditional prescribing approaches in clinical therapies, such as ‘trial and error’, ‘one drug fits all’ and ‘one 
dose fits all’, have limits due to the drug safety. Pharmacogenetics combines standard biochemical tests with molecular 
genetics based tests to detect DNA variations in the human genome for the application of genomic-based prescribing.
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2.2. Polymorphisms as biomarkers for drug response and toxicity
Variations in the metabolism of a chemotherapeutic agent due to genetic alterations 
may cause significant differences in terms of efficacy and toxicity. Such pharmacological 
effects occur since oncologists schedule the dosing of chemotherapeutic agents accord-
ing to patient’s body surface area and other nongenetic factors. Genetic differences due to 
the polymorphisms are thought as one of the strongest reasons in adverse drug reactions 
(ADRs). Genetic polymorphisms are considered as molecular biomarkers in pharmacoge-
netic-based studies both in clinic and research to predict the ADRs and apply the medica-
tions as personal. The main objective of pharmacogenetics is to understand the nature of 
various responses including adverse drug reactions (ADRs) to drugs [22]. Pharmacogenetic 
associations are important in cancer chemotherapy due to the extremely narrow chemo-
therapeutic index of anticancer drugs given for cancer management. Polymorphisms in 
both patient’s genome and tumor genome affect the regulation of drug transport, reten-
tion and efflux of anticancer drugs, determining the penetration into tumor tissue. Genetic 
information of tumors is not stabile as somatic tissues; new alterations on genetic mate-
rial (as mutation or chromosomal loss) can occur continuously. Therefore, drug-related 
toxicities depend on the genotype of nontumor tissue. Thus, the tumor genome possesses 
most of the polymorphisms that influence the sensitivity or resistance of drugs (KRAS and 
EGFR, KIT, TS polymorphisms, etc.); hence, treatment efficacy and tumor genome will have 
a key role as a dose limiting factors in cancer management. Polymorphisms on the host 
Method Advantages Disadvantages
Allele-specific single-base 
primer extension
High success rate;
High accuracy;
Quantitative;
Adaptation to multiplexing.
High instrument cost;
Relatively long protocol;
Tricky multiplex PCR.
Allele-specific enzymatic 
cleavage – restriction fragment 
length polymorphism (RFLP)
High accuracy;
SNP at a restriction endonuclease 
recognition sequence.
High instrument cost;
Long protocol;
Difficult adaptation for high-throughput 
genotyping
Pyrosequencing Provides sequence information 
surrounding the polymorphism;
Real-time scoring;
Quantitative.
High instrument and consumable cost;
Long protocol;
Limited throughput
Mass spectrometry High accuracy (as long as the sample is 
very pure);
Fast genotyping reactions in seconds;
Allows thousands of reactions in a day.
High instrument and consumable cost;
Long protocol;
Limited throughput;
Requires very pure sample for accuracy.
Invader assay No PCR for amplification;
Simple protocol;
Isothermal reaction
Requires large amount of genomic DNA;
Requires optimizations for each SNP;
Key enzyme is not suitable for general 
research use.
Table 1. A summary of popular polymorphism detection methods with their advantages and disadvantages [19–21].
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genome, which tumor genome does not present, are the main determinants of toxicity risk 
(e.g.  polymorphisms on the genes of drug  metabolism such as dihydropyrimidine  dehydrogenase 
gene (DPYD),  thiopurine-S-methyltransferase (TPMT), UDP-glucuronosyltransferase (UGT), etc.) 
[23]. Genotyping studies have revealed that the gene encoding a specific protein can have a 
number of differences in sequence at the nucleotide level. These differences especially called 
as polymorphisms, sometimes do not cause significant alterations on the final product, but 
may have an effect on the substrate specificity and activity of the product (especially for 
enzymes) or other characteristics and functions. For example, polymorphisms in cytochrome 
P450 2D6 (CYP2D6) are one of the cytochrome P450 enzymes of the liver that can influ-
ence how humans metabolize cancer drugs, although the enzymes are basically the same 
sequence and structure. Polymorphisms in CYP2D6 have been seen in the general popula-
tion about 10% and it has been associated with poor-metabolizer phenotype of enzyme. 
This is important for codeine-based pain medications due to the activation of codeine to 
morphine and includes CYP2D6-dependent step [24].
Pharmacogenetic tests based on the determination of genetic variants for drug efficacy or 
toxicity has begun to use in the 2000s, although genetic-based studies began in the 1950s. FDA 
has been working to improve pharmacogenetic technologies in the development, regulation 
and use of medications and revised drug labels in terms of pharmacogenetic biomarkers in 
oncology area (Table 2) [25, 26].
It is important to describe important gene polymorphisms and their clinical meaning in 
oncology field that may determine the optimum pharmacological treatment in terms of 
treatment outcomes, tolerability and the occurrence of serious, even life-threatening adverse 
reactions.
Pharmacogenetic biomarker Drugs Labeling Outcome
UGT1A1 Irinotecan
Belinostat
Nilotinib
Pazopanib
Dose determination and administration;
Warnings and precautions, clinical pharmacology
Toxicity
DPYD Capecitabine
Fluorouracil
Warnings and precautions, patient counseling 
information
Toxicity
TPMT Cisplatin Adverse reactions Toxicity
Mercaptopurine
Thioguanine
Dose determination and administration;
Warnings and precautions; Adverse reactions;
Clinical pharmacology
Toxicity
G6PD Rasburicase 
Dabrafenib
Warnings and precautions; Contraindications;
Adverse reactions;
Patient counseling information
Toxicity
CYP2D6 Tamoxifen 
Rucaparib
Dose determination and administration;
Clinical pharmacology
Toxicity
Table 2. FDA-approved pharmacogenetic biomarkers for anti-cancer drug labeling [26].
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2.2.1. Uridinediphosphate glucuronosyl transferase 1A1 (UGT1A1)
The UGT super family includes four main UGT families, namely UGT1, UGT2, UGT3, and 
UGT8. The UGT1 and UGT2 genes, encode 16 functional proteins, have been extensively 
studied and well characterized. A phase II metabolic enzyme, UGT1A1 is the most studied 
UGT enzyme due to its main role in glucuronidation of exogenous and endogenous sub-
strates, including bilirubin. UGT1A1 also appears in the metabolism processes of most of the 
anti-cancer drugs, such as topoisomerase I inhibitor irinotecan, the topoisomerase II inhibi-
tor etoposide [27]. Alterations on the glucuronidation activity of UGT1A1 caused by genetic 
or environmental factors may have significant physiological and pharmacological results 
on the metabolism of anticancer agents. Allelic variations have been identified in the pro-
moter region and exon 5 of UGT1A1 region. The wild-type allele of UGT1A1 gene (known 
as UGT1A1*1) has six thymine- adenine (TA) repeats in the promoter region of gene (TATA 
box). Allelic differences vary from five (UGT1A1*36, proficient allele) to eight (UGT1A1*37, 
 deficient allele) TA repeats, and these differences affect the UGT1A1-mediated glucuronida-
tion of SN-38 (7-ethyl-10-hydroxycamptothecin), active metabolite of anticancer drug irino-
tecan both in vitro and in vivo. Increasing number of TA repeats has been associated with 
decreased transcription of gene and overall UGT1A1 activity (Table 3) [28]. Patients (allele 
frequency in Caucasians 8–20% are homozygous, 40–50% are heterozygous) with seven TA 
repeat sequence (named UGT1A1*28) have severe toxicity risk after irinotecan treatment 
because of decreased gene expression and overall UGT1A1 activity (30% enzyme activity in 
*28 relative to *1 allele). These patients [with (TA)7 repeats] have fourfold relative toxicity risk 
compared with patients with six repeat sequences [29]. UGT1A1*60 (in linkage disequilib-
rium with TATA box variants) and UGT1A1*93 are the other variants located in the promoter 
region. Both of them are found homozygous in around 10% of Caucasians [30]. UGT1A1*6 
and UGT1A1*27 are located in coding region exon 1. UGT1A1*6 is the most frequent variant 
in Asian populations (not found in Caucasians) and associated with ~30% decreased enzyme 
activity in homozygous patients. UGT1A1*27 is almost completely eradicated enzyme activ-
ity. Nearly 3% of Asian people, are homozygous for both *6 and *27 variant [28, 31].
2.2.2. Dihydropyrimidine dehydrogenase gene (DPYD)
The pyrimidine antimetabolites 5-fluorouracil and its oral prodrug capecitabine are widely 
used chemotherapeutic agents in the management of variety of tumor types, including colorec-
tal, breast, and head and neck cancers. They activate metabolically and inhibit thymidylate 
synthase enzyme, which takes role in cellular replication. However, 5-FU leads significant 
toxicities, such as myelosuppression, mucositis, hand-foot syndrome, and diarrhea. On the 
other hand, accumulation of knowledge on 5-FU mechanism has developed new strategies 
that increase the treatment efficacy and response [32, 33]. 5-FU is metabolized by dihydropy-
rimidine dehydrogenase (DPD) enzyme, and it converts the fluoropyrimidine to its inactive 
metabolite dihydrofluorouracil (Figure 3). DPD enzyme, which is encoded by DPYD gene, is 
a rate-limiting enzyme of 5-FU catabolism and is also used for evaluating the variability of 
5-FU metabolism among patients [34]. SNPs in the DPYD gene are responsible for insufficient 
production of DPD enzyme; therefore, low levels of enzyme increase the half-life of the drug, 
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Genotype Ref SNP HGVS
Region
Drug Enzymatic activity
Clinical phenotype
UGT1A1*1 Common allele-Wild type (TA) 6TA Irinotecan Normal enzyme activity
UGT1A1*28 rs 8175347 (TA) 7 TA
TATA box
Irinotecan Reduced enzyme activity
*1/*28 Irinotecan dosing based on clinical 
findings
*28/*28 Dose reduction recommended.
UGT1A1*36 rs 8175347 (TA) 5 TA
TATA box
Irinotecan Normal enzyme activity
Irinotecan dosing recommendations are less 
clear.
UGT1A1*37 rs 8175347 (TA) 8 TA
TATA box
Irinotecan Normal enzyme activity
Irinotecan dosing recommendations are less 
clear.
UGT1A1*60 rs 4124874 c.-3279T>G
Promoter region
Irinotecan Normal enzyme activity
Standard irinotecan dosing
UGT1A1*93 rs10929302 c.-3156G>A
Promoter region
Irinotecan Normal enzyme activity
Standard irinotecan dosing
DPYD*9A rs1801265 c.85T>C, p.Cys29Arg
Exon 2
5-fluorouracil Capecitabine Normal enzyme activity
Standard irinotecan dosing
DPYD*2A rs3918290 IVS14 + 1G>A
Intron 14 and exon 14
5-fluorouracil Capecitabine Reduced enzyme activity
Increased toxicity risk
DPYD*13 rs55886062 c.1679T>G, p.Ile560Ser
Exon 13
5-fluorouracil Capecitabine Reduced enzyme activity
Increased toxicity risk
TYMS 2R/2R,
TYMS 2R/3RG, TYMS 
3RG/3RG,
rs34743033 28bp VNTR (2R; 3R)
Promoter enhancer region
5-fluorouracil Capecitabine Enzyme activity based on the repeats
2R/2R: Decreased TYMS expression, increased 
5-FU responsiveness, increased risk of toxicity
2R/3RG, 3RG/3RG: Increased TYMS 
expression, decreased 5-fluorouracil, 
capecitabine responsiveness, poor prognosis.
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Genotype Ref SNP HGVS
Region
Drug Enzymatic activity
Clinical phenotype
TYMS 3RG/3RC,
TYMS 2R/3RC,
TYMS 3RC/3RC
rs2853542 G>C SNP in 2nd repeat of 3R 
allele (3RC)
Promoter enhancer region
5-fluorouracil Capecitabine Enzyme activity based on the repeats
3RG/3RC: Increased TYMS expression, 
decreased 5-FU responsiveness, poor prognosis
2R/3RC or 3RC/3RC: Decreased TYMS 
expression, increased 5-FU responsiveness, 
increased risk of toxicity
MTHFR, 677C>T rs1801133 c.677C>T, p.Ala222Val
Exon 4
Methotrexate Reduced enzyme activity
Homozygosity: Risk for toxicity from drugs 
and requirement for dosing adjustments/
discontinuation
Heterozygosity: Associated with intermediate 
enzyme activity
Lower dose requirements for methotrexate
MTHFR, 1298A>C rs1801131 c.1298A>C; p.Glu429Ala
Exon 7
Methotrexate Reduced enzyme activity
Homozygosity/Heterozygosity: Associated 
with intermediate enzyme activity. Lower dose 
requirements for methotrexate.
TPMT*1 Common allele-Wild type Common allele-Wild type 6-mercaptopurine;
Azathioprine; Thioguanine
Normal enzyme activity
TPMT*2 rs1800462 c.238G>C, p.Ala80Pro
Exon 5
6-mercaptopurine; 
Azathioprine; Thioguanine
Poor activity
Homozygosity: very low/absent enzyme 
activity
Heterozygosity: intermediate activity
Low/Absent Activity: Increased risk for 
developing life-threatening side effects at a 
standard dose of a thiopurine drug.
Intermediate (Reduced) Activity: Increased 
risk for toxicity at a standard dose of a 
thiopurine drug.
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Genotype Ref SNP HGVS
Region
Drug Enzymatic activity
Clinical phenotype
TPMT*3A rs1800460
rs1142345
c.[460G>A;719A>G],
p.[Ala154Thr;Tyr240Cys]
Exon 7, 10
6-mercaptopurine; 
Azathioprine; Thioguanine
Poor activity
Homozygosity—Low/Absent Activity: Increased 
risk for developing life-threatening side effects 
from a standard dose of a thiopurine drug.
Heterozygosity- Intermediate (Reduced) 
Activity: Increased risk for toxicity from a 
standard dose of a thiopurine drug.
TPMT*3B rs1800460 c.460G>A, p.Ala154Thr
Exon 7
6-mercaptopurine, 
Azathioprine, Thioguanine
Poor activity
Homozygosity—Low/Absent Activity: 
Increased risk for developing life-threatening 
side effects at a standard dose of a thiopurine 
drug.
Heterozygosity—Intermediate (Reduced) 
Activity: Increased risk for toxicity at a standard 
dose of a thiopurine drug.
TPMT*3C rs1142345 c.719A>G, p.Tyr240Cys
Exon 10
6-mercaptopurine, 
Azathioprine, Thioguanine
Poor activity
Homozygosity—Low/Absent Activity: Increased 
risk for developing life-threatening side effects 
from a standard dose of a thiopurine drug.
Heterozygosity—Intermediate (Reduced) 
Activity:
Increased risk for toxicity from a standard dose 
of a thiopurine drug.
CYP2D6*1 Common allele-Wild type Common allele-Wild type Tamoxifen Normal activity
Extensive metabolizer
CYP2D6*2 rs16947 c.584G>c, p.Arg296Cys
Exon 2
Tamoxifen Normal enzyme activity
CYP2D6*4 rs3892097 1846G>A
Exon 3—Junction of intron 3 
and exon 4
(Not applicable variant occurs 
in a noncoding region)
Tamoxifen Inactive enzyme
Polymorphisms in Pharmacogenetics of Personalized Cancer Therapy
http://dx.doi.org/10.5772/intechopen.69207
13
Genotype Ref SNP HGVS
Region
Drug Enzymatic activity
Clinical phenotype
CYP2D6*5 Whole gene deletion
On allele
Tamoxifen Inactive enzyme
CYP2D6*6 rs5030655 c.1707delT, p.Trp152Gly
Exon 3
Tamoxifen Inactive enzyme
CYP2D6*9 AGA deletion at 2613-2615, 
p.Lys281 del
Tamoxifen Reduced enzyme activity
(Partially functioning)
CYP2D6*10 rs1065852 c.188C>T, p.Pro34Ser
Exon 1
Tamoxifen Reduced enzyme activity
CYP2D6*17 rs28371706
rs16947
c.320C>T, p.Thr107Ile;
c.886T>C, p.Cys296Arg
Intron 1
Tamoxifen Reduced enzyme activity
CYP2D6*41 rs28371725 c.2988G>A
Intron 6
(Not applicable variant occurs 
in a noncoding region)
Tamoxifen Reduced enzyme activity
Note: Guidelines for the description and nomenclature of gene variations are available from the Human Genome Variation Society (HGVS): http://www.hgvs.org/content/
guidelines.
Table 3. Biological impact of the important pharmacogenetic biomarker variants [28, 42–46].
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thus, resulting in excess drug accumulation and toxicity due to the inefficient catabolism of 
drug. Genetic testing of polymorphisms is being used for the classification of patients who 
would be at high risk for severe or fatal toxicity when receiving fluoropyrimidine-based che-
motherapy (Table 3) [35]. Complete deficiency of DPD has been seen in approximately 5% of 
the overall population and also 3–5% of the population has a partial DPD deficiency due to 
sequence variations in DPYD gene [36].
The IVS14+ 1G>A change with the combination of a mutation in intron 14 and a deletion 
at 5′-splice consensus sequence of exon 14, the most known and frequent variant (known as 
DPYD*2A), is resulting the formation of a truncated enzyme product lacking activity. The 
estimated incidence of homozygous genotype of this allelic variant is 0.1% and heterozy-
gous genotype is 0.5–2.0% in Caucasians [37, 38]. Other variants, which are associated with 
increased toxicity risk, include 496A>G in exon 6, T1679G (DPYD*13) in exon 13 and 2846A>T 
in exon 22 [39–41]. Genetic mutations in DPYD can be analyzed by highly sensitive methods 
even for heterozygous variants such as pyrosequencing. But determination of the 5-FU and 
dihydrofluorouracil concentration ratio in plasma by high-pressure liquid chromatography 
(HPLC) may be more reliable predictor test for toxicity [35]. Besides DPYD, there are some 
other pharmacogenetic biomarkers that are being used for the determination of the efficacy 
and toxicity of fluoropyrimidine-related therapies, such as thymidylate synthase gene (TYMS).
2.2.3. Thymidylate synthase gene (TYMS)
The main intracellular target of fluoropyrimidine-related therapies is to inhibit thymidylate 
synthase (TS) enzyme (encoded by the TYMS gene) that catalyzes the transformation of dUMP, 
Figure 3. Metabolism of 5-fluorouracil (5-FU). The initial and rate-limiting enzyme of 5-FU is dihydropyrimidine 
dehydrogenase (DPD), catalysing the conversion of 5-FU into 5,6-dihydrofluorouracil (DHFU). DHFU is degraded 
into fluoro-beta-ureidopropionic acid (FUPA) and fluoro-beta-alanine (FBAL) through degradation cascade. 5-Fluoro-
2′-deoxyuridine-5′-monophosphate (5-FdUMP), is the cytotoxic product resulting from a multi-step activation of 
5-FU, inhibits the enzyme thymidylate synthase (TS) enzyme. This inhibition leads to accumulation of deoxy-uridine-
monophospate (dUMP) and depletion of deoxy-thymidine-monophosphate (dTMP), which leads to inhibition of DNA 
synthesis. 5-FU can also inhibit RNA synthesis in a pathway that involves 5-fluorouridine monophosphate (5-FUMP) 
and subsequent conversion to 5-fluorouridine triphosphate (5-FUTP) via 5-fluorouridine diphosphate (5-FUDP).
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which is essential for DNA replication (Figure 3) [47]. Fluorodeoxyuridylate (5-FdUMP), an 
activated metabolite from 5-FU, forms stable complexes with TS enzyme and folate to stop 
DNA synthesis over blocking the conversion of dUMP to dTMP. Therefore, low expression 
levels of TS enzyme in colorectal patients receiving 5-FU-based treatment were associated 
with desired drug response as well as to longer survival [47]. Polymorphisms, which lead 
TYMS variations (2R/2R, 2R/3R, or 3R/3R) by forming double-tandem repeat (2R) or a triple-
tandem repeat (3R) on the TYMS promoter enhancer region (generally abbreviated as TSER), 
influence the translation of TYMS mRNA and toxicity (Table 3). It has been showed that 
homozygous 3R/3R cells overexpressed TYMS mRNA compared with homozygous 2R/2R 
cells [48]. Apart from these repeats, a G>C SNP has been showed on the 12th nucleotide of the 
second repeat at 3R allele, and it is causing a tri-allelic locus as 2R, 3RG, and 3RC. The 3RC 
allele has similar transcriptional activity of the 2R allele [49]. Another genetic polymorphism 
of the TYMS gene has been identified as a 6 basepair deletion at position 1494 in the 3′-untrans-
lated region (3′-UTR). It was demonstrated that there is a strong association between the 6-bp 
deletion and low TYMS mRNA expression in colorectal tumor tissue [50, 51].
2.2.4. Methylene tetrahydrofolate reductase (MTHFR)
Methylene tetrahydrofolate reductase (MTHFR) a regulatory enzyme is involved in folate 
metabolism that redirects folate metabolites from pyrimidine synthesis towards methionine 
synthesis (Figure 3). Most of the MTHFR gene variants of enzyme contain polymorphisms 
that lead loss-of-function in the enzyme (Table 3). The level of loss-of-function depends on 
the type and number of polymorphisms in coding gene. Therefore, MTHFR polymorphisms 
affect drug metabolism, such as methotrexate, may be more likely to experience toxicity. 
c.677C>T (p.A222V) and c.1298A>C (p.G429A) are the most common polymorphisms of 
MTHFR gene that forms abnormal forms of enzyme. Both polymorphisms are associated 
with reduced MTHFR enzyme activity. Adjustment drug dosages and prediction of the tox-
icity risk, MTHFR polymorphism test may be performed for a patient who is treated with 
 methotrexate [23].
2.2.5. Thiopurine-S-methyltransferase (TPMT)
Thiopurine-S-methyltransferase (TPMT) enzyme, encoding by TPMT gene, catalyzes the 
S-methylation of thiopurine drugs (such as 6-mercaptopurine, azathioprine, and thiogua-
nine) for drug inactivation. The purine antimetabolites are converted to active thioguanine 
nucleotides that can be incorporated into DNA or RNA to block the DNA replication. During 
this activation process, purine antimetabolites cause cellular toxicity for both malign and 
benign cells. TPMT catalyzes inactivation of the formed thioguanine nucleotides [52]. It is 
known that some patients have low enzyme activity due to germline genetic variations. There 
are several TPMT polymorphisms that caused more than 20 variant alleles of TPMT gene 
(from TPMT*2 to TPMT*20) and have different effects on TPMT function (Table 3). Among 
these variant alleles TPMT*2, TPMT*3A, TPMT*3B, and TPMT*3C have been determined as 
responsible for enzyme deficiency. Among these alleles TPMT*2, TPMT*3A and TPMT*3C are 
deficient alleles that present poor enzyme activity [45]. Accumulation of cytotoxic  thiopurine 
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nucleotides leading to severe toxicity has been shown in people with deficient TPMT alleles, 
after receiving a standard dose thiopurine-based treatment. Patients with low TPMT activ-
ity expose more activated thioguanine nucleotides and more treatment toxicity as well as 
efficacy. Patient’s genotype predicts thiopurine nucleotide levels and treatment outcomes in 
thiopurine drug metabolism that shows tri-modal distribution with 89–94% of patients hav-
ing high enzyme activity, 6–11% of them having intermediate activity (as heterozygous), and 
0.3% of them having low or no activity (as homozygous) [53].
2.2.6. Glucose-6-phosphate dehydrogenase (G6PD)
Glucose-6-phosphate dehydrogenase (G6PD) is a metabolic enzyme involved in pentose 
phosphate pathway that is important in red blood cell metabolism. The G6PD gene is highly 
polymorphic with more than 300 variants. G6PD gene deficiency is a common disease-caus-
ing enzymopathy and is associated with low levels of G6PD enzyme. The most remarkable 
symptom of G6PD gene deficiency is hemolytic anemia caused by the ingestion of drugs and 
food substances that result in oxidative stress. The excess peroxide due to deficiency has a risk 
for both hemolytic and methemoglobinemia. Rasburicase is a recombinant urate oxidase that 
has been used for the initial management of plasma uric acid in pediatric and adult patients 
with leukemia, lymphoma and solid tumors who are receiving chemotherapeutic agents and 
are expected for tumor lysis syndrome. Rasburicase is contraindicated in patients with G6PD 
gene deficiency; therefore, FDA recommends screening for G6PD deficiency before beginning 
rasburicase treatment. Dabrafenib is a kinase inhibitor that blocks the growth and spread of 
cancer cells in the body. Dabrafenib consists of a sulfonamide moiety and contains hemo-
lytic anemia risk in patients with G6PD deficiency. Thus, FDA recommends monitoring for 
patients with G6PD deficiency started with dabrafenib [54–56].
2.2.7. Cytochrome P450 2D6 (CYP2D6)
Cytochrome P450 2D6 (CYP2D6) deficiency is the first discovered pharmacogenetic deficiency 
with the characterization of decreased enzyme expression-related polymorphisms. Decreased 
mRNA levels of CY2D6 were determined as the reason of reduced metabolism and adverse 
reactions to an anti-hypertensive drug, debrisoquine. These findings based on molecular tech-
nologies display the importance of genotyping on the pharmacological phenotyping involved 
in drug metabolism [35]. CYP2D6 is a highly polymorphic enzyme (Table 3). According to 
increased or decreased enzyme activity due to SNPs, duplications or deletions, genetic vari-
ants of CYP2D6 were classified into four metabolic phenotypes: ultra-rapid metabolizer, 
extensive metabolizer, intermediate metabolizer and poor metabolizer (Table 4). This classifi-
cation system has been used to control treatment recommendations for several drugs, includ-
ing tamoxifen [57].
Tamoxifen is a selective estrogen receptor modulator, which is used in the treatment of estrogen 
receptor-positive breast cancer. Tamoxifen is a weak estrogen antagonist by itself, but it is con-
verted into its main active metabolite, antiestrogenic endoxifen, by CYP2D6. CYP2D6 genotype is 
predictive of endoxifen exposure that is critical in determining treatment outcome [59]. Increased 
endoxifen exposure is associated with increased treatment efficacy and toxicity [60, 61].
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2.3. Biomarker discovery studies for pharmacogenetic applications
Pharmacogenetics and its backbone studies in terms of polymorphisms present new devel-
opments and trends in the field of tailored medications and advancements in the modifi-
cation of therapeutic choices utilizing genotypic information from polymorphism analysis. 
Pharmacogenetic biomarker studies have multiple processes from discovery to clinical imple-
mentation (Figure 4). The ultimate aim of the biomarker studies is to find a clinically accessible 
decision-maker biomarker to improve patient outcomes. However, many of the valid associa-
tions cannot be achieved for clinical implementation due to the lack of sufficient robustness 
or clinical importance for the question. Biomarker discovery studies should be performed 
as the screening of genotype-phenotype relations in large cohorts with statistical and bioin-
formatics tools. The most significant markers obtained from discovery studies are replicated 
for analytical validation in different cohorts with the evaluation of assay reproducibility and 
robustness. After successful analytical validity, the biomarker and assay must be evaluated 
to confirm its performance in diagnosing the clinical phenotype or predicting outcome of 
Phenotype Genotype
Poor metabolizer Two inactive alleles
Intermediate metabolizer Two active alleles
Extensive metabolizer One active and one inactive alleles;
Two decreased activity alleles;
One decreased activity and one inactive allele
Ultra-rapid metabolizer More than two copies of active allele
Notes: Active alleles: *1, *2, *33, *35; decreased activity alleles: *9, *10, *17, *29, *36, *41; inactive alleles: *3, *4, *5, *6, *7, 
*8, *11-*16, *19-*21, *38, *40, *42.
Table 4. CYP2D6 phenotypes according to activity status of CYP2D6 alleles (adapted from Swen JJ., et al. 2011) [58].
Figure 4. Schematic presentation of pharmacogenetic biomarker studies from development to clinical implementation.
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interest. A clinically valid biomarker assay can undergo translation through prospective con-
firmation of clinical utility to improve patient outcomes. And finally, analytically and clini-
cally validated biomarker assay is ready for implementation phase that includes regulatory 
approval and incorporation in clinical practice guidelines, commercialization and coverage 
by health insurance [52, 62].
2.4. Future directions and conclusion
After “Human Genome Project,” science world began to use individual genotypic informa-
tion to predict the risk of diseases, to prognose the disease, to guide therapeutic decision-
making, and to develop targeted medications. Especially, the better prediction ability for 
drug response and life-threatening toxic reactions is highly crucial for clinicians due to the 
narrow therapeutic index of many cancer chemotherapeutic agents. The aim of personal-
ized medicine is to prescribe a convenient chemotherapeutics to the right patients with right 
dose to achieve maximal therapeutic benefit with minimal toxicity. Deep observation of the 
human genome is still ongoing, and it will help to discover new targets and select the most 
efficacious drug for each patient’s tumor, which is named as genomic prescribing system, 
the next  evolution of systemic cancer management. Genetic polymorphisms, as significant 
biomarkers, have provided significant and crucial information in the management of toxic-
ity and dosing of cancer treatments. So far the achievements have been limited due to the 
multifactorial challenges on the polymorphism-based personalized cancer management. 
Especially reliable clinical data for the effects of genetic alterations on the disease patho-
genesis, drug metabolism and response are not always available; and performing the large-
scale prospective clinical studies, to understand the associations of polymorphisms and the 
application of chemotherapeutics, is often laborious. However, these prospective studies are 
required for establishing possible relations for evaluating the utility and cost-effectiveness of 
polymorphism-based pharmacogenetic tests and personalized medicine. Ethical, social, and 
regulatory issues relevant with pharmacogenetic-based personalized medicine are the other 
complex and challenging factors to establish the relations between genetic polymorphisms 
and personalized drug responses.
The main application of genetic polymorphism knowledge is improving the futuristic health 
care through gene therapy, discovery of new drugs and drug targets and upgrade the discov-
ery processes with advanced technologies. The use of single candidate genes can be useful as 
a part of initial treatment, but in near future, it will never be enough to provide fully tailored 
treatment decisions on the cancer management. Other omics technologies will complement 
the genotype-phenotype association-based pharmacological-pathway approach, such as tran-
scriptomics, epigenomics, and miRNAomics.
2.4.1. Polymorphism and pharmacogenetics facts
• Humans share about 99.9% sequence identity. The other 0.1% are mostly SNPs.
• SNPs are the most common polymorphism type and occur about every 1000 bases.
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• SNPs can be silent—99% of them are not in coding regions and not in genes and thus cause 
harmless, harmful, latent changes.
• Genetic polymorphisms are one of the most important factors that may contribute to ethnic 
sensitivity of a drug.
• FDA recommends for following guidelines relating to “ethnically sensitive situations” for 
some drugs and suggests solutions that may control such ethnic sensitivity in the context 
of therapeutic applications and study designs.
• The Hardy-Weinberg principle can be used to calculate allele frequencies.
• Hardy-Weinberg principle-based reporting may be optimal in genetic polymorphism-
based studies.
• Personalized medicine separates patients into different groups with an individual’s mo-
lecular profile and covers the determination of the safest and most effective chemothera-
peutic agents.
• The aim of pharmacogenetics is to make ‘personalized medicine’ as applicable to various 
patient groups.
• Although a number of good polymorphism genotyping technologies are currently in use 
to meet the needs of clinics and researches, not only one genotyping method is ideal for 
all applications. Studies on ideal polymorphism genotyping technologies are still ongoing.
• FDA has been working to improve pharmacogenetics technologies in the development, 
regulation and use of medications and revise drug labels in terms of pharmacogenetic bio-
markers in oncology area.
• Polymorphism in the DPYD gene is responsible for insufficient production of DPD en-
zyme; therefore, low levels of enzyme increase drug accumulation and toxicity due to the 
inefficient catabolism of drug.
• Allelic differences of UGT1A1 affect the glucuronidation of SN-38, active metabolite of iri-
notecan both in vitro and in vivo.
• TPMT polymorphisms have different effects on function of TPMT that inactivates thio-
guanine nucleotides. Patients with low TPMT activity expose more activated thioguanine 
nucleotides and more treatment toxicity as well as efficacy.
• FDA recommends screening for G6PD deficiency before the beginning of rasburicase 
treatment.
• CYP2D6 deficiency is the first discovered pharmacogenetic deficiency. Genetic variants of 
CYP2D6 are classified into ultra-rapid metabolizer, extensive metabolizer, intermediate 
metabolizer, and poor metabolizer.
• Biomarker development studies involve multiple steps, as biomarker assay development, 
analytical validation, clinical validation, and clinical implementation.
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